Adjuvant chemotherapy indeed enhanced disease-free survival and overall survival in stage III patients, who had only BRCA1-negative tumours (p < 0.001, p < 0.001, respectively), but not in patients with BRCA1-positive tumours (p = 0.236, p = 0.148, respectively). This evidence concerns the gene BRCA1 and neoplasm.